Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at The Johns Hopkins Hospital, and completed a Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson’s publications include the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer, and the first description of kidney retransplantation performed after immunotherapy–related organ rejection. Based on his published work, Dr. Lipson initiated a clinical trial testing a novel combination of immune-based therapies for kidney transplant recipients with advanced selected cancers. Results from this trial - the first of its kind - were reported in 2022 at an international oncology meeting. Dr. Lipson is a leader in the clinical development of relatlimab, an antibody blocking the LAG-3 immune checkpoint. He leads a phase 2 trial testing combination immune checkpoint inhibitor therapy—including anti-LAG-3—for patients with advanced basal cell carcinoma. In June 2021, Dr. Lipson presented findings from the first phase 3 study establishing the LAG-3 pathway as the third immune checkpoint pathway in history, after CTLA-4 and PD-1, for which blockade has clinical benefit. This trial supported the FDA's approval of a new therapy for patients with advanced melanoma. In addition to his research activities, Dr. Lipson is an educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs. Dr. Lipson conducts regular clinical practices in Baltimore, Maryland and at Sibley Memorial Hospital in Washington, D.C. as part of the multidisciplinary Melanoma Program at Johns Hopkins. Dr. Lipson is rated as an Elite provider by MediFind in the treatment of Merkel Cell Carcinoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Pancreaticoduodenectomy.

Dr. William H. Sharfman is an associate professor of oncology and dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous oncology, dermatology and immunotherapy. He helped create the well-established Melanoma Program at the Johns Hopkins Kimmel Cancer Center in 1994. Dr. Sharfman serves as the director of cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program. He earned his M.D. from the University of Toledo College of Medicine. He completed his residency at Cleveland Clinic and performed a fellowship in hematology and oncology at Cleveland Clinic. Dr. Sharfman's research interests include novel therapies for high risk and advanced melanoma patients. Dr. Sharfman is rated as an Elite provider by MediFind in the treatment of Merkel Cell Carcinoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Eccrine Porocarcinoma, and Familial Pancreatic Cancer.

Isaac Brownell is a Dermatologist in Bethesda, Maryland. Dr. Brownell is rated as an Elite provider by MediFind in the treatment of Merkel Cell Carcinoma. His top areas of expertise are Merkel Cell Carcinoma, Muir-Torre Syndrome, Warts, and Nummular Eczema.

Dr. Topalian is a physician-scientist whose studies of anti-tumor immunity have been foundational in developing cancer immunotherapy. She has published over 160 original research articles and reviews in this area and is one of the most highly cited researchers in the biomedical field. She received her medical and scientific training at Tufts University School of Medicine, Thomas Jefferson University Hospital, Children’s Hospital of Philadelphia and the National Cancer Institute. She joined the Johns Hopkins Kimmel Cancer Center in 2006 as the inaugural director of its Melanoma Program. Dr. Topalian is credited with advancing the clinical development of anti-PD-1 immunotherapy, and her work is widely recognized. She was named one of Nature’s 10 in 2014, and received the Karnofsky Award from ASCO in 2015, the Taubman Prize in 2016, the NCI’s Rosalind E. Franklin Award in 2018, the American Academy of Dermatology’s Gruber Memorial Cancer Research Award in 2020, and the Award for Distinguished Research in the Biomedical Sciences from the Association of American Medical Colleges in 2021 for landmark discoveries in cancer immunotherapy. Dr. Topalian was elected to the National Academy of Medicine in 2017, and to the American Association for Cancer Research Academy in 2022. Her work has opened new avenues of scientific investigation and established immunotherapy as a pillar of oncology. Dr. Topalian is rated as a Distinguished provider by MediFind in the treatment of Merkel Cell Carcinoma. Her top areas of expertise are Merkel Cell Carcinoma, Melanoma, Neuroendocrine Tumor, and Anal Cancer.

Dr. Janis Taube is a professor of dermatology and pathology at the Johns Hopkins University School of Medicine and a member of the Johns Hopkins Kimmel Cancer Center. Her area of clinical expertise is dermatopathology. Dr. Taube serves as the Director of the Division of Dermatopathology and as the Assistant Director of the Dermatoimmunology Laboratory at the School of Medicine. Dr. Taube received her undergraduate degree in engineering from Duke University. She earned her M.D. from Tulane University and her M.Sc. in molecular medicine from University College London. She completed her residency in pathology at Johns Hopkins where she also served as the chief resident, before undertaking a dermatopathology fellowship at Stanford University. In 2009, Dr. Taube returned to Johns Hopkins for her certification in the Melanoma Clinic. She is one of the lead scientific researchers in the Department of Dermatology at Johns Hopkins. She has written over 180 peer-reviewed publications, and her research has been cited over 70,000 times. In addition to running her own research laboratory, she serves as the co-Director of the Mark Foundation Center for Advanced Genomics and Imaging and also as the co-Director of the Tumor Microenvironment Core Laboratory for the Bloomberg~Kimmel Institute for Cancer Immunotherapy. Dr. Taube is rated as a Distinguished provider by MediFind in the treatment of Merkel Cell Carcinoma. Her top areas of expertise are Melanoma, Merkel Cell Carcinoma, Basal Cell Skin Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), and Pancreaticoduodenectomy.

Md Siddiqui is a Hematologist Oncology specialist and a Hematologist in Salisbury, Maryland. Dr. Siddiqui is rated as an Experienced provider by MediFind in the treatment of Merkel Cell Carcinoma. His top areas of expertise are Pulmonary Embolism, Inflammatory Breast Cancer, Angiosarcoma, and Childhood Iron Deficiency Anemia. Dr. Siddiqui is currently accepting new patients.

"Dr. Fariba Asrari is the director of Johns Hopkins Breast Center at Green Spring Station. She received her medical degree with honors from Shiraz Medical School in Iran and completed Internal medicine residency training at affiliated Hospitals of University of Pennsylvania in Philadelphia. She then completed her second residency training in Radiation Oncology at Hahnemann university in Philadelphia. She is an active member of the American Society for Therapeutic Radiology and Oncology as well as the American Medical Association, American Radium Society, Mid-Atlantic Society of Radiation Oncologists and American Society of Clinical Oncology. She is the treasurer of Mid-Atlantic Society of Radiation Oncologists. Dr. Asrari's special interest is in breast and gynecologic malignancies as well as skin cancer. She also participates in resident and medical student teaching. She is the recipient of 2006 Director's Teaching Award in Clinical Science at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and 2006 ""Teacher of The Year Award"" of Association of Residents in Radiation Oncology. She also has received 2005 Thomas Fercoit Memorial Professional of The Year Award from ""The ARC of Baltimore"" in appreciation of her dedicated care of individuals with developmental disabilities. Make A Gift". Dr. Asrari is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. Her top areas of expertise are Breast Cancer, Prostate Cancer, Merkel Cell Carcinoma, and Angiosarcoma.

Dr. Joel Sunshine is an Assistant Professor of Dermatology, Pathology, Oncology, and Biomedical Engineering at the Johns Hopkins University School of Medicine. He specializes in medical dermatology and skin cancer. His areas of clinical expertise include general dermatology, cutaneous oncology including melanoma and Merkel cell carcinoma, and supportive oncodermatology. Dr. Sunshine obtained his undergraduate degree from Brandeis University, his M.D. and Ph.D. from Johns Hopkins University School of Medicine, and his dermatology residency training and dermatopathology fellowship from the Northwestern University Feinberg School of Medicine. Dr. Sunshine is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. His top areas of expertise are Merkel Cell Carcinoma, Melanoma, Familial Atypical Multiple Mole Melanoma Syndrome, and Hidradenitis Suppurativa.

Dr. Julie Lange is an assistant professor of surgery, dermatology and oncology at the Johns Hopkins University School of Medicine. Dr. Lange was one of the original members of the Johns Hopkins melanoma group when it was first formed in 1995 and now serves as a clinical co-director of the Melanoma Program. Dr. Lange introduced the sentinel node technique to Johns Hopkins for both melanoma and breast cancer in the 1990s and has extensive experience with this technique. Dr. Lange is a graduate of the Vanderbilt University School of Medicine and completed her general surgery training at Yale-New Haven Hospital. She completed a fellowship in surgical oncology and immunotherapy at the Surgery Branch of the National Cancer Institute as well. Dr. Lange joined the faculty of the Department of Surgery at Johns Hopkins in 1994 and subsequently earned a Sc.M. in clinical investigation at the Johns Hopkins Bloomberg School of Public Health. She has particular interest in melanoma at extremes of age, and in the factors associated with variance in melanoma care. Dr. Lange has published the largest study of melanoma in children, adolescents and young adults. She recognizes that melanoma in the older patient is a growing epidemic and has investigated the socioeconomic, demographic and healthcare factors that influence the treatment of melanoma in older persons. Dr. Lange is a member of the melanoma panel of the National Comprehensive Cancer Network, a group that annually evaluates and revises national treatment guidelines for melanoma. In 2015, she was inducted for her work into the Miller-Coulson Academy of Clinical Excellence, which recognizes outstanding clinicians at Johns Hopkins based on a number of factors, including communication and interpersonal skills, professionalism and humanism, a scholarly approach to clinical practice, and a passion for patient care. Dr. Lange is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. Her top areas of expertise are Melanoma, Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Lymphadenectomy.

William Burns, M.D., is an assistant professor of surgery at the Johns Hopkins University School of Medicine and a surgeon within the Division of Hepato-Pancreato-Biliary & Gastrointestinal Surgical Oncology at The Johns Hopkins Hospital. Prior to joining the faculty at Johns Hopkins, Dr. Burns served as an assistant professor of surgery at the University of Michigan, as well as an attending physician at the University of Michigan Health Systems and the VA Ann Arbor Healthcare System. Dr. Burns received his medical degree from Yale University School of Medicine and was awarded a research training fellowship by the Howard Hughes Medical Institute. He completed an internship and residency in general surgery at The Johns Hopkins Hospital followed by clinical fellowship training in complex general surgical oncology at The University of Texas MD Anderson Cancer Center. Additionally, he completed postgraduate research fellowships in the field of cancer immunotherapy and tumor immunology at the National Cancer Institute and the MD Anderson Cancer Center. Dr. Burns specializes in treating patients with tumors of the pancreas and gastrointestinal tract, sarcoma and melanoma. He is trained in traditional and minimally invasive surgical techniques. Furthermore, he works closely with colleagues in medical and radiation oncology to provide comprehensive cancer care. His research focuses on immune cell-tumor cell interactions to improve outcomes in patients with pancreatic cancer, cancer immunotherapy for solid tumors, the role of lymph node surgery in the treatment of cancer, and human biospecimen analysis to guide therapy in patients with cancer. He is a member of several professional societies, including the American College of Surgeons, Society of Surgical Oncology, Association of Academic Surgery, and Society of Immunotherapy for Cancer. Dr. Burns is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. His top areas of expertise are Neuroendocrine Tumor, Familial Pancreatic Cancer, Familial Colorectal Cancer, Small Bowel Resection, and Pancreatectomy.

Julie Woods is a Hematologist Oncology specialist and a Hematologist in Bel Air, Maryland. Dr. Woods is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. Her top areas of expertise are Anal Cancer, Familial Colorectal Cancer, Small Cell Lung Cancer (SCLC), and Lung Cancer. Dr. Woods is currently accepting new patients.

Glen Gibson is a Surgical Oncologist and a General Surgeon in Annapolis, Maryland. Dr. Gibson is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. His top areas of expertise are Familial Pancreatic Cancer, Melanoma, Familial Colorectal Cancer, Hernia Surgery, and Hepatectomy. Dr. Gibson is currently accepting new patients.

Kaveh Zakeri is a Radiation Oncologist in Charlotte Hall, Maryland. Dr. Zakeri is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. His top areas of expertise are Laryngeal Cancer, Throat Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Merkel Cell Carcinoma, and Gastrostomy.

Joseph Bennett is a General Surgeon and a Surgical Oncologist in Randallstown, Maryland. Dr. Bennett is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. His top areas of expertise are Pancreatic Adenoma, Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatectomy, and Small Bowel Resection. Dr. Bennett is currently accepting new patients.

Edward Mccarron is a General Surgeon and a Surgical Oncologist in Glen Burnie, Maryland. Dr. Mccarron is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. His top areas of expertise are Melanoma, Familial Pancreatic Cancer, Ogilvie Syndrome, Hernia Surgery, and Pancreatectomy. Dr. Mccarron is currently accepting new patients.

Linda Wang is a Dermatologist in Lutherville, Maryland. Dr. Wang is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. Her top areas of expertise are Spider Angioma, Telangiectasia, Intertrigo, and Rosacea. Dr. Wang is currently accepting new patients.

Neha Amin is a Radiation Oncologist in Bel Air, Maryland. Dr. Amin is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. Her top areas of expertise are Pleuropulmonary Blastoma, Familial Pancreatic Cancer, Pancreatic Cancer, and Vulvar Cancer.

Nataliya Melnyk is a Hematologist Oncology specialist and a Hematologist in Bel Air, Maryland. Dr. Melnyk is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. Her top areas of expertise are Iron Deficiency Anemia, Essential Thrombocythemia, Childhood Iron Deficiency Anemia, and Pulmonary Embolism.

Vadim Gushchin is a Surgical Oncologist in Lutherville, Maryland. Dr. Gushchin is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. His top areas of expertise are Pseudomyxoma Peritonei, Colorectal Cancer, Familial Colorectal Cancer, Ureteral Reconstruction, and Small Bowel Resection. Dr. Gushchin is currently accepting new patients.

Jason Taksey is an Oncologist and a Hematologist in Columbia, Maryland. Dr. Taksey is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. His top areas of expertise are Urothelial Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, and WT1-Related Wilms Tumor Syndromes. Dr. Taksey is currently accepting new patients.